These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 38022528)

  • 21. Expression of the IL-6 receptor alpha-chain (CD126) in normal and abnormal plasma cells in monoclonal gammopathy of undetermined significance and smoldering myeloma.
    Salem DA; Korde N; Venzon DJ; Liewehr DJ; Maric I; Calvo KR; Braylan R; Tembhare PR; Yuan CM; Landgren CO; Stetler-Stevenson M
    Leuk Lymphoma; 2018 Jan; 59(1):178-186. PubMed ID: 28540748
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Monoclonal gammopathy and smoldering multiple myeloma: diagnosis, staging, prognosis, management.
    Hillengass J; Moehler T; Hundemer M
    Recent Results Cancer Res; 2011; 183():113-31. PubMed ID: 21509683
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Laboratory testing for monoclonal gammopathies: Focus on monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
    Willrich MAV; Murray DL; Kyle RA
    Clin Biochem; 2018 Jan; 51():38-47. PubMed ID: 28479151
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of bone marrow biopsy in patients with plasma cell disorders: should all patients with a monoclonal protein be biopsied?
    Sidiqi MH; Aljama M; Kumar SK; Jevremovic D; Buadi FK; Warsame R; Lacy MQ; Dingli D; Gonsalves WI; Fonder AL; Hobbs MA; Hwa YL; Kapoor P; Kourelis T; Leung N; Muchtar E; Lust JA; Kyle RA; Go RS; Rajkumar VS; Gertz MA; Dispenzieri A
    Blood Cancer J; 2020 May; 10(5):52. PubMed ID: 32376870
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Risk Stratification of Precursors to Multiple Myeloma in 2020.
    Chudasama R; Barth P
    R I Med J (2013); 2020 Apr; 103(3):46-47. PubMed ID: 32236162
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Stromal alterations in patients with monoclonal gammopathy of undetermined significance, smoldering myeloma, and multiple myeloma.
    Bogun L; Koch A; Scherer B; Fenk R; Maus U; Bormann F; Köhrer K; Petzsch P; Wachtmeister T; Zukovs R; Dietrich S; Haas R; Schroeder T; Jäger P; Geyh S
    Blood Adv; 2024 May; 8(10):2575-2588. PubMed ID: 38241490
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Does my patient with a serum monoclonal spike have multiple myeloma?
    Bianchi G; Ghobrial IM
    Hematol Oncol Clin North Am; 2012 Apr; 26(2):383-93, ix. PubMed ID: 22463833
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Monoclonal Antibodies in Smoldering Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance: Current Status and Future Directions.
    Ferla V; Farina F; Perini T; Marcatti M; Ciceri F
    Pharmaceuticals (Basel); 2024 Jul; 17(7):. PubMed ID: 39065751
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The diagnostic value of SE MRI and DWI of the spine in patients with monoclonal gammopathy of undetermined significance, smouldering myeloma and multiple myeloma.
    Dutoit JC; Vanderkerken MA; Anthonissen J; Dochy F; Verstraete KL
    Eur Radiol; 2014 Nov; 24(11):2754-65. PubMed ID: 25106487
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Role of T Cell Immunity in Monoclonal Gammopathy and Multiple Myeloma: From Immunopathogenesis to Novel Therapeutic Approaches.
    Lagreca I; Riva G; Nasillo V; Barozzi P; Castelli I; Basso S; Bettelli F; Giusti D; Cuoghi A; Bresciani P; Messerotti A; Gilioli A; Pioli V; Colasante C; Vallerini D; Paolini A; Maccaferri M; Donatelli F; Forghieri F; Morselli M; Colaci E; Leonardi G; Marasca R; Potenza L; Manfredini R; Tagliafico E; Trenti T; Comoli P; Luppi M
    Int J Mol Sci; 2022 May; 23(9):. PubMed ID: 35563634
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Monoclonal gammopathy of ocular significance (MGOS) - a short survey of corneal manifestations and treatment outcomes.
    Garderet L; Al Hariri M; Wasielica-Poslednik J; Munder M; Kormányos K; Pena C; Gozzetti A; Zhou X; Waszczuk-Gajda A; Rosinol L; Mikala G; Krzystanski M; Lisch W; Vesole D; Szentmáry N; Jurczyszyn A
    Leuk Lymphoma; 2022 Apr; 63(4):984-990. PubMed ID: 34823428
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
    Cesana C; Klersy C; Barbarano L; Nosari AM; Crugnola M; Pungolino E; Gargantini L; Granata S; Valentini M; Morra E
    J Clin Oncol; 2002 Mar; 20(6):1625-34. PubMed ID: 11896113
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Analysis of the Targets and Glycosylation of Monoclonal IgAs From MGUS and Myeloma Patients.
    Bosseboeuf A; Seillier C; Mennesson N; Allain-Maillet S; Fourny M; Tallet A; Piver E; Lehours P; Mégraud F; Berthelot L; Harb J; Bigot-Corbel E; Hermouet S
    Front Immunol; 2020; 11():854. PubMed ID: 32536913
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Correlation between Morphological Typing and Monoclonality of Bone Marrow Plasma Cells and Its Diagnostic Value for High-Risk Smoldering Multiple Myeloma].
    Xiao HJ; Wang QJ; Wu S; Dai XB; Zhuang YP
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Aug; 32(4):1146-1151. PubMed ID: 39192411
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Monoclonal IgG in MGUS and multiple myeloma targets infectious pathogens.
    Bosseboeuf A; Feron D; Tallet A; Rossi C; Charlier C; Garderet L; Caillot D; Moreau P; Cardó-Vila M; Pasqualini R; Arap W; Nelson AD; Wilson BS; Perreault H; Piver E; Weigel P; Girodon F; Harb J; Bigot-Corbel E; Hermouet S
    JCI Insight; 2017 Oct; 2(19):. PubMed ID: 28978808
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
    Kyle RA
    Eur J Haematol Suppl; 1989; 51():70-5. PubMed ID: 2516809
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Smoldering Multiple Myeloma: Observation Versus Control Versus Cure.
    Rajkumar SV; Bergsagel PL; Kumar S
    Hematol Oncol Clin North Am; 2024 Apr; 38(2):293-303. PubMed ID: 38158241
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
    Kyle RA; San-Miguel JF; Mateos MV; Rajkumar SV
    Hematol Oncol Clin North Am; 2014 Oct; 28(5):775-90. PubMed ID: 25212882
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PD-L1/PD-1 Pattern of Expression Within the Bone Marrow Immune Microenvironment in Smoldering Myeloma and Active Multiple Myeloma Patients.
    Costa F; Vescovini R; Marchica V; Storti P; Notarfranchi L; Dalla Palma B; Toscani D; Burroughs-Garcia J; Catarozzo MT; Sammarelli G; Giuliani N
    Front Immunol; 2020; 11():613007. PubMed ID: 33488620
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Smouldering multiple myeloma: To seek or not to seek? To treat or not to treat. That is the question.
    Vaxman I; Gatt ME
    Br J Haematol; 2024 Apr; 204(4):1141-1142. PubMed ID: 38429858
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.